To keep up to date with news from this category use our
Theratechnologies presents combined Phase 3 clinical results at European AIDS Conference
Montr
IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies
NORWALK, CT, November 11, 2009 - IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology...
BrainStorm Chief Medical Advisor Interviewed on Israel Radio Broadcast; States Stem Cell Therapy Treatment Ready For Clinical Trials
New York and Petach Tikvah, Israel - November 11, 2009 - BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that its chief...
Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cervical Spinal Cord Injury
MENLO PARK, Calif., November 11, 2009 - Geron Corporation (Nasdaq: GERN) today announced the publication of data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when...
AMT Successful in Preclinical Treatment of DMD
Amsterdam, The Netherlands - November 11, 2009 - Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has successfully treated Duchenne muscular...
Capario Launches Updated Version of Its Revenue Cycle Management Portal for Providers
SANTA ANA, Calif., November 11, 2009 -- Capario, a leading provider of revenue cycle management solutions that connect healthcare payers and providers nationwide, today announced a new release of its revenue cycle...
Simcyp Simulator aids in preclinical ADME assessment of Genentech compound
November 11, 2009--A recent paper, by researchers at Genentech, describes the preclinical evaluation of the pharmacokinetic properties of GDC-0449, a potent selective Hedgehog signalling pathway inhibitor which is being...
The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma
Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug NGR-hTNF in the...
Mobidiag Launches Rapid DNA Microarray Technology for Diagnostics of Bone and Joint Infections
Birmingham, United Kingdom, November 11, 2009 - Finnish molecular diagnostics company Mobidiag releases rapid microarray solution for identifying bacteria responsible for bone and joint infections (BJIs). Enhancing the...
Viron to Present Data from Phase II Trial at American Heart Association Conference
London, Canada -November 11, 2009-- Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr....
SRI International and F. Hoffmann-La Roche Launch Translational Medicine Collaboration to Study Methods and Treatments Associated with Cognitive Deficits across Neuropsychiatric Disorders
MENLO PARK, Calif.--November 10, 2009--SRI International, an independent nonprofit research and development organization, announced today that its Center for Neuroscience has entered into a research collaboration with...
Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb
Schlieren (Zurich), Switzerland, November 10, 2009 - Cytos Biotechnology Ltd (SIX:CYTN) today gave an update on the development of its hypertension vaccine CYT006-AngQb. In a first phase IIa study (study 01) the vaccine...
IRONWOOD AND ASTELLAS ANNOUNCE JAPAN LICENSING AGREEMENT FOR LINACLOTIDE
CAMBRIDGE, Mass. and TOKYO, Japan, November 10, 2009-- Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and...
Cerimon Pharmaceuticals Acquires European Rights to Topical Diclofenac Patch Cerimon Also Completes Enrollment of Phase 3 Diclofenac Patch Studies in Acute Pain Company Also Receives Notice of Allowance for Key US Patent Application
SOUTH SAN FRANCISCO, Calif. -November 10, 2009 - Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in...
BIOVEX COMPLETES $70 MILLION FINANCING TO CONCLUDE PIVOTAL STUDY WITH ITS PIONEERING CANCER TREATMENT, ONCOVEXGM-CSF
Woburn, MA, November 10, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private...
Update on CSD500
November 10, 2009 -- Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces an update on progress towards the marketing authorisation of its lead...
Cytokinetics Announces Advancement of CK-2017357 in Phase I Clinical Trials
South San Francisco, CA - November 9, 2009--Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the initiation of a double-blind, randomized, placebo-controlled, multiple-dose Phase I clinical trial to investigate...
Scientists Launch Effort to Sequence the DNA of 10,000 Vertebrates
November 05, 2009 -- Scientists have an ambitious new strategy for untangling the evolutionary history of humans and their biological relatives: a genetic menagerie made of the DNA of more than 10,000 vertebrate...
Phase Forward Signs Multi-Year Agreement with Quotient Clinical for Use of InForm(TM) Electronic Data Capture Solution
WALTHAM, Mass.----Nov. 5, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with Quotient Clinical, which...
Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, Calif.-- November 4, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company's development candidates have been accepted for presentation at the 2009...
Antigenics Provides Details On GlaxoSmithKline's Pivotal Malaria Vaccine Trial With QS-21 Adjuvant
LEXINGTON, MA - November 4, 2009 - Antigenics, Inc. (NASDAQ: AGEN) today indicated that GlaxoSmithKline's (GSK) Phase III malaria vaccine clinical trial, containing Antigenics' QS-21 Stimulon
AlphaVax Progresses a Prophylactic HSV Vaccine
November 04, 2009--The development of an effective prophylactic vaccine against herpes simplex virus (HSV) is a key product opportunity for which the AlphaVax vector platform is ideally suited. [HSV Program]. Recently,...
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the...
Phase Forward Teams with PharmaNet Development Group
WALTHAM, Mass.---Nov. 4, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year agreement with PharmaNet Development Group,...
Phase Forward to Present at the 18th Annual Credit Suisse Healthcare Conference
WALTHAM, Mass.----Nov. 4, 2009-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its senior vice president and chief financial officer,...
Phase Forward Announces Share Repurchase Program
WALTHAM, Mass.--Nov. 4, 2009-- Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced today that its board of directors has authorized...
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
ROCKVILLE, Md., November 4, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has completed the sale of PentaStaph(TM) (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline PLC (GSK). The...
Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
NOVATO, Calif., Nov. 4, 2009 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP), today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be...
New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting
November 04, 2009 -- Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA.
Cellectis bioresearch launches cGPS
Paris, November 4, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launched cGPS
Ortho Clinical Diagnostics Launches First-of-its-kind Remote Monitoring Center 24 Hour Central Command Center now Offers Predictive and Proactive Diagnostic Monitoring Service in Eight Languages to Clinical Laboratories in 18 Countries Using VITROS
Paris, France (November 4th, 2009) Ortho Clinical Diagnostics (OCD) today announced the launch of a first-of-its-kind 24-7 central command center in Strasbourg, France, that continuously tracks the condition of clinical...
Inspire Completes Patient Enrollment in Three Late-Stage Clinical Trials in Cystic Fibrosis, Dry Eye and Blepharitis
DURHAM, N.C.-- November 4, 2009-- Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials.
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Strasbourg, France, November, 4th, 2009 - Transgene S.A. (Euronext Paris: FR0005175080) today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical...
Nabi Biopharmaceuticals Initiates Pivotal Phase III Study for NicVAX as an Aid to Smoking Cessation and Long-term Abstinence
ROCKVILLE, Md., November 3, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has initiated the first of two pivotal Phase III clinical trials for NicVAX(R) (Nicotine Conjugate Vaccine), the company's...
Databases locked in both the phase III clinical studies with SBG for diabetic foot ulcer
November 03, 2009--Biotec Pharmacon is pleased to inform that all data management procedures have been completed, and that the databases have been locked in both of the company's phase III studies with soluble...
BIOLASE Introduces the Diolase 10(TM) Diode Laser for Pain Management, Therapeutic Applications
IRVINE, CA, Nov 03, 2009 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, today announced the launch of the Diolase 10(TM) Diode Laser for therapeutic applications, including...
MediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
SAN DIEGO, November 3, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:...
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive Officer of ViiV...
Enobia Pharma Expands Clinical Program for ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia
MONTREAL, November 3, 2009 -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia...
Almac Launches Unique Site-specific PEGylation Technology at BIO Europe
November 02, 2009--Almac's site-specific Ligation technology takes advantage of impressive expertise in production and engineering of both recombinant proteins and synthetic peptides to develop a proprietary technology...
BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEXGM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY
Woburn, MA, November 2, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2...
IRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM TWO PIVOTAL PHASE 3 TRIALS IN PATIENTS WITH CHRONIC CONSTIPATION
CAMBRIDGE, Mass. and New York, November 2, 2009 -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top line results from two Phase 3 clinical trials assessing the safety...
Pharsight Launches Phoenix NLME(TM), Continues to Build Next-Generation Platform for Model-Based Drug Development
ST. LOUIS, MO - November 2, 2009 - Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix...
PHASE ONE COMPLETE AT PENN PHARMA
November 02, 2009--Leading bioscience company, Penn Pharma has completed the first phase of its
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
Monday 2nd November 2009, London UK & Philadelphia US --GlaxoSmithKline PLC (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Benlysta(TM) (belimumab) met the primary endpoint in BLISS-76, the...
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers
November 02, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and...
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
MISSISSAUGA, ON, Nov. 2 , 2009 - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
ROCKVILLE, MD (November 2, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent...
Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting
SAN DIEGO- October 31, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
October 30, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the...
Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
Vienna, Austria, October 30, 2009 - Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO
Bayer HealthCare Pharmaceuticals (BAY) Presents Florbetaben Phase II Study Results at World Congress of Neurology
BANGKOK, Oct. 30 -- Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of...
Echo Therapeutics Announces Significant Advance in Development of its One-Piece, Needle Free Symphony tCGM Biosensor
FRANKLIN, Mass., October 29, 2009 -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal...
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
MOUNTAIN VIEW, Calif., October 29, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's...
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises
VIENNA, Va., Oct. 26 -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common...
ORTHO CLINICAL DIAGNOSTICS LAUNCHES FETALSCREEN(TM) II FETAL MATERNAL HEMORRHAGE SCREENING TEST
RARITAN, N.J. (Oct. 23, 2009) - Ortho Clinical Diagnostics announced the launch of FETALSCREEN(TM) II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho) positive fetal red blood...
Bayer and Onyx Initiate Phase III Trial of Nexavar
Berlin, October 23, 2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'
GHENT, Belgium, 23 October 2009 - Ablynx [Euronext Brussels: ABLX] is pleased to announce it has been awarded ,,Most Successful Early Phase Trial' at the 2009 Good Clinical Practice Journal's (GCPj) Clinical Research...
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix(TM), and preliminary paediatric results
October 23, 2009 -- GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix(TM), as part of Government initiated vaccination programmes across...
Strategic Collaboration with Kineta
MATTAWAN, MI October 23, 2009: MPI Research announced that it will be collaborating with Kineta, Inc, a Seattle-based biotechnology company, in advancing their promising autoimmune drug development program. This...
Movetis obtains EU authorisation for the commercialisation of Resolor
Turnhout, October 22, 2009 Movetis, the GI specialty pharmaceutical company based in Belgium, announces that it has obtained approval from the European Commission for the commercialisation of its lead product Resolor...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22 -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
Ophthalmic Imaging Systems to Launch OIS EyeScan and Other New Products at the American Academy of Ophthalmology's (AAO) 113th Annual Meeting
SACRAMENTO, CA--(10/22/09) - Ophthalmic Imaging Systems ("OIS" or "the Company") (OTC.BB:OISI - News), a leading digital imaging and informatics company, today announced that it will launch two new products and...
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
SAN DIEGO, Oct 22, 2009 -- Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze(TM) technology (rHuPH20, recombinant human...
SciClone Announces Enrollment of First Patient in Its Phase 2 Trial of SCV-07 in Hepatitis C
FOSTER CITY, CA, Oct 21, 2009 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of its first patient at the Atlanta Gastroenterology Associates in Atlanta, GA, in a phase 2 trial of SCV-07...
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...
Sanofi-aventis and Wellstat Therapeutics enter into an Exclusive Worldwide Licensing Agreement for novel oral agent to treat Type II Diabetes
Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral first-in-class, insulin...
Novavax and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
Rockville, MD and Marlborough, MA - October 21, 2009 - Novavax, Inc. (NASDAQ: NVAX) and Xcellerex, Inc. has entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
PharmaNet Development Group Management Participates In The 8th Annual Partnerships In Clinical Trials Conference In Rotterdam
Princeton, NJ - October 21, 2009 - PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its...
Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...
Gore Announces First Implant of Next Generation Conformable GORE TAG
October 20, 2009--W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG
Sernova's Cell Pouch System(tm) and Sertolin(tm) Preclinical Efficacy Presented at Leading International Islet Transplant Conference
LONDON, ONTARIO--(Oct. 20, 2009) - Sernova Corp. (TSX VENTURE:SVA - News) is pleased to provide a summary of results of islet transplantation studies related to its Cell Pouch System(TM) and Sertolin(TM) technologies...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22-- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients
SOUTH SAN FRANCISCO, CA (October 15, 2009) - Phase 1/2 clinical trial results with KB001, a Humaneered(TM), high-affinity antibody fragment under development by KaloBios Pharmaceuticals, Inc. in cystic fibrosis patients...
Interim analysis of an ongoing phase II study with nicotine vaccine shows primary endpoint not achieved
Schlieren (Zurich), Switzerland, October 15, 2009 - Cytos Biotechnology Ltd (SIX:CYTN) was informed today by Novartis that an interim analysis of a Phase II study with the nicotine vaccine NIC002 showed that the primary...
Optimata Releases a New Version of its Virtual Patient
October 13, 2009---Optimata Ltd announces the release of a new Optimata Virtual Patient
Jessica Biel, Alexandra Cousteau, Pete Wentz, Angelique Kidjo, and Jenny Fletcher Join Live Earth, Global Water Challenge and Dow to Launch the Dow Live Earth Run For Water - the Largest Global Water Initiative in History to Help Solve the World Water Crisis
New York - October 13, 2009 --Today, Live Earth announced plans to implement the largest worldwide water initiative on record to help combat the global water crisis. The Dow Live Earth Run for Water - to take place...
Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes
MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
GE HEALTHCARE CONTINUES ADVANCEMENT OF NUCLEAR MEDICINE WITH LAUNCH OF DISCOVERY NM/CT 670
Barcelona, Spain October 11, 2009 - GE Healthcare, a unit of General Electric Company (NYSE:GE), announced the European launch of Discovery NM/CT 670, a hybrid imaging platform designed to improve workflow, dose...
Lpath's iSONEP Is Well Tolerated at All Dose Levels in a Phase 1 Trial in Wet-AMD Patients
SAN DIEGO, CA, October 08, 2009 -- Lpath, Inc. (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP(TM) in wet-AMD...
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
MENLO PARK, Calif.--Oct. 5, 2009-- Depomed, Inc. (NASDAQ:DEPO) today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically...
Changed definition of safe contraception in clinical trials
Danish Medicines Agency, 2 October 2009--We have updated section 5.1 Contraception in the Guideline for applications for authorisation of clinical trials of medicinal products in humans.
I-Flow Corporation Receives 510(k) Clearance From FDA for Oxygenated Topical Dressing Company to Now Start Clinical Studies on First of Its Kind Oxygen
LAKE FOREST, Calif.--Sept. 24, 2008--I-Flow Corporation (NASDAQ: IFLO), through its wholly-owned subsidiary AcryMed Inc., announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA)...
ZOOM 1.3 GUI Release (Next Gen Seq)
Waterloo, ON, September 24, 2009--Canada- Bioinformatics Solutions Inc. announces the launch of next generation sequencing software, ZOOM Studio 1.3, in a user-friendly GUI, integrating the short sequence mapping,...
Luna Technologies Launches New Optical Vector Analyzer
ROANOKE, Va -- September 17, 2009-- Luna Technologies, an industry-leading developer of advanced solutions for fiber optic test and measurement systems and a division of Luna Innovations Incorporated (NASDAQ: LUNA),...
iBio Completes $3 Million Private Placement
NEWARK, DE - September 10, 2009 - iBio, Inc. (OTCBB: IBPM) today announced a private placement of approximately $3 million of its common stock principally to current stockholders who previously purchased the Company's...
CathRx announces commencement of pilot trial for its irrigated ablation catheter
Sydney 17 June 2009: Cardiac catheter manufacturer CathRx Ltd (ASX: CXD) today announced it had commenced a human pilot trial of its first therapeutic catheter for use in both atrial flutter and atrial fibrillation...
Scienion Launches Microfluidic sciSWIFTER - Joint commercialization with Matrical Bioscience
Dortmund, Germany, and Spokane, WA, USA, January 12, 2009: Scienion AG and Matrical Bioscience recently announced the launch of the sciSWIFTER(TM), a new dispensing device developed for high precision dispensing in 96,...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
